R to @europainitalia: Tra l'altro, abbiamo discusso su come stimolare l'innovazione e gli investimenti, inclusi attraverso il #BiotechAct.
3/4
---
https://nitter.net/europainitalia/status/2049909369232347231#m

.@OliverVarhelyi: Attraverso il #BiotechAct e l'Omnibus sulla sicurezza degli animali e dei mangimi, stiamo rafforzando il ruolo dell'EFSA - per accelerare le valutazioni mantenendo gli standard più elevati.

Oliver Varhelyi (@OliverVarhelyi)

Through the #BiotechAct and Food & Feed Safety Omnibus, we are strengthening EFSA’s role - to speed up assessments while maintaining the highest standards.

https://nitter.net/OliverVarhelyi/status/2049470044820685202#m
---
https://nitter.net/europainitalia/status/2049479739002224840#m

Europe's biotech gap must close.

We back the @EU_Commission #BioTechAct and call for:
🔬 an ecosystem linking research & production;
🔬 permanent investment tools;
🔬 a central role for the European Medicines Agency;
🔬 stronger clinical trials for all patients.

Europe's biotech gap must close.

We back the @EU_Commission #BioTechAct and call for:
🔬 an ecosystem linking research & production;
🔬 permanent investment tools;
🔬 a central role for the Europ...
---
https://nitter.net/EU_EESC/status/2044317298996203664#m

RT by @EU_Health: Today, I met with @EORTC representatives: non-commercial clinical trials are instrumental to optimise treatments, improve outcomes, and support accessible, tailored cancer care, enhancing patients’ quality of life.

The #BiotechAct and #PharmaReform will help make this easier.
---
https://nitter.net/OliverVarhelyi/status/2023744840513564724#m

Europe urged to fill US mRNA tech gap: Recent US retreat in mRNA vaccines and therapies could open the door for Europe in its upcoming #BiotechAct. https://www.euractiv.com/section/health-consumers/news/eu-risks-biotech-setback-if-mrna-tech-is-left-out-of-biotech-act/?utm_source=mastodon&utm_medium=dlvr.it